Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

VNDABullishIndustry Newsnews

High materiality7/10

Vanda's Nereus Phase 3 data could unlock GLP-1 tolerability opportunity

Oct 27, 2026, 2:35 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong Phase 3 signals and a clear regulatory path (FDA discussion and sNDA) can re-rate VNDA higher, especially given the 50B+ GLP-1 market and the potential for broader uptake if tolerability improves.

AI summary

What happened, with direct paths to the underlying reporting

Vanda reported Phase 3 results for Nereus (tradipitant), aimed at reducing vomiting from GLP-1 therapies in a market exceeding $50B. The data show meaningful benefits, including a 27% relative vomiting reduction and a 60% drop in frequent vomiting, supporting an sNDA for label expansion after FDA discussion. If approved, tolerability improvements could broaden GLP-1 adoption and VNDA's growth path.

Phase 3 shows 27% relative vomiting reduction with Nereus vs placebo.
43% vomiting in Nereus group vs 58.5% placebo.
Post-hoc: 60% drop in frequent vomiting; extreme vomiting down 81%.
FDA discussion planned; sNDA to expand Nereus label.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Vanda's Nereus Phase 3 data could unlock GLP-1 tolerability opportunity

Vanda's VQW-765 Phase III failure triggers hold and near-term VNDA downside

Vanda Pharmaceuticals Soars After FDA Approves Bysanti Treatment

VNDA Soars After FDA Approval for Bysanti in Mental Health Treatments

US FDA approves Vanda's psychiatric drug